NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of investors who purchased Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NasdaqCM:GALT) securities between January 6, 2014 and July 28, 2014.
For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt.
The complaint alleges that during the Class Period, the Company violated federal securities laws by issuing false and misleading statements regarding its business and prospect. As a result of these statements, Galectin stock traded at artificially inflated prices.
On July 28, 2014, an article featured on TheStreet.com noted that Galectin hired a stock promotions firm known as Emerging Growth Corp. to tout its stock. The article further notes that Emerging Growth “describes itself as an investor relations and marketing company, but that it’s just a shiny façade on what is really an ugly penny-stock promotions scheme.” The following day, Galectin reported disappointing results regarding its phase 1 experimental drug trial for GR-MD-02.
If you suffered a loss in Galectin you have until September 29, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/galectin-therapeutics-galt.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.